Story perspectives

Summit Therapeutics' Ivonescimab Shows Promise Despite Survival Concerns

9/7/2025

48 5

Summary

Story summary

Summit Therapeutics' PD-1xVEGF drug, ivonescimab, achieved a 48% reduction in disease progression risk in the HARMONi phase 3 trial.
Long-term follow-up indicated a 33% progression-free survival benefit in Western patients, compared to 44% in Chinese patients.
The trial did not meet its overall survival endpoint, showing only a 21% reduction in death risk.
Summit plans to pursue FDA approval but is cautious due to immature overall survival data.
Analysts are concerned about result consistency between Chinese and Western populations, though improved overall survival data offers hope.

1 of 1

Story summary

Summit Therapeutics' PD-1xVEGF drug, ivonescimab, achieved a 48% reduction in disease progression risk in the HARMONi phase 3 trial.
Long-term follow-up indicated a 33% progression-free survival benefit in Western patients, compared to 44% in Chinese patients.
The trial did not meet its overall survival endpoint, showing only a 21% reduction in death risk.
Summit plans to pursue FDA approval but is cautious due to immature overall survival data.
Analysts are concerned about result consistency between Chinese and Western populations, though improved overall survival data offers hope.